NDA 209512 · Abbvie
Norvir
Ritonavir · Oral · Cytochrome P450 3A Inhibitor; Protease Inhibitor
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Jun 7, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,048
265 Phase 3, 24 recruiting
FAERS reports
29,122
26,508 serious, 2,649 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism of certain drugs. Review medications taken by patients prior to prescribing NORVIR or when prescribing other medications to patients already taking NORVIR [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 )]. WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS See full prescribing information for complete boxed warning Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in...
What it is approved for
From the label in effect Jul 23, 2026.
NORVIR tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. NORVIR oral powder is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1 infection. NORVIR tablets are HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection ( 1 ) NORVIR oral powder is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1 infection ( 1 )
Mechanism: Ritonavir is an antiretroviral drug [see Microbiology ( 12.4 ) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- NORVIR · RITONAVIR 100MG/PACKET · POWDER, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ritonavir" as an intervention, any sponsor and status, largest first.
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT04353180 · 100,000 participants (planned) · Start Aug 2021 · Primary completion Oct 2021
Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment; Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment and 3 more · For: COVID19
Sites: Cairo, Egypt · 2 sites in all
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Pivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT05041907 · 3,800 participants (planned) · Start Sep 30, 2021 · Primary completion Jan 2027
Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™); Nitazoxanide and 16 more · For: COVID-19
Sites: Minas Gerais, Brazil; Vientiane, Laos; Kathmandu, Nepal · 7 sites in all
- Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited CountriesPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01061151 · 3,747 participants · Start Mar 1, 2011 · Primary completion Sep 30, 2016
Drug: Zidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers and 6 more · For: HIV Infections
Sites: Pune, India; Blantyre, Malawi; Lilongwe, Malawi · 14 sites in all
- Preventing Sexual Transmission of HIV With Anti-HIV DrugsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00074581 · 3,526 participants · Start Feb 2005 · Primary completion May 2015
Drug: Atazanavir; Didanosine and 8 more · For: HIV Infections
Sites: Boston, Massachusetts; Gaborone, Botswana; Nova Iguaçu, Brazil · 17 sites in all
- A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 InfectionPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05047601 · 2,954 participants · Start Sep 9, 2021 · Primary completion Apr 12, 2022
Drug: PF-07321332; Placebo for PF-07321332 and 2 more · For: COVID-19
Sites: Pelham, Alabama; Tucson, Arizona; Fullerton, California · 170 sites in all
- Breastfeeding, Antiretroviral, and Nutrition StudyPivotal-lookingCompleted
Centers for Disease Control and PreventionFederal agency
NCT00164736 · 2,369 participants · Start Mar 2004 · Primary completion Jan 2010
Drug: Maternal zidovudine/lamivudine/lopinavir-ritonavir; Infant nevirapine · For: HIV Infections
Sites: Lilongwe, Malawi
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug interaction2,561
- foetal exposure during pregnancy2,398
- anxiety1,622
- pain1,573
- emotional distress1,388
- maternal exposure during pregnancy1,245
- anhedonia1,235
- nausea1,056
- diarrhoea1,021
- exposure during pregnancy1,015
- renal failure951
- fatigue906
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 569 |
| 2005 | 619 |
| 2006 | 798 |
| 2007 | 909 |
| 2008 | 1,077 |
| 2009 | 1,368 |
| 2010 | 1,352 |
| 2011 | 1,246 |
| 2012 | 1,488 |
| 2013 | 1,465 |
| 2014 | 1,585 |
| 2015 | 2,154 |
| 2016 | 2,283 |
| 2017 | 1,802 |
| 2018 | 1,932 |
| 2019 | 1,715 |
| 2020 | 1,901 |
| 2021 | 1,434 |
| 2022 | 1,370 |
| 2023 | 913 |
| 2024 | 564 |
| 2025 | 384 |
| 2026 | 192 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Jul 24, 2026
Norvir, Oral Powder, 100 mg (NDC 0074-3399-30). Discontinuation of the manufacture of the drug
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Norvir (Ritonavir)
2024 spending
$566K
Beneficiaries
266
1,508 claims
Per beneficiary
$2,129
$8.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,536,814 |
| 2021 | $1,550,102 |
| 2022 | $1,128,899 |
| 2023 | $753,472 |
| 2024 | $566,195 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J, Leister-Tebbe H, Gardner A, et al. · N Engl J Med 2022 · Clinical Trial, Phase II, Randomized Controlled Trial
- Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis.
Ibrahim S, Siemieniuk RAC, Oliveros MJ, et al. · BMJ 2025 · Network Meta-Analysis, Systematic Review
- Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis.
Wang Y, Yang Y, Shan R, et al. · J Infect Dev Ctries 2024 · Systematic Review, Meta-Analysis
- Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
Butler CC, Pinto AD, Harris V, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Equivalence Trial
- Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
Hammond J, Yunis C, Fountaine RJ, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
Cao Z, Gao W, Bao H, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Comparative Study
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.